Nanomedicine makes use of
nanoparticles for developing newer drug delivery systems against
cancer, diabetes, fungal infections and viral infections
The remarkable properties of various nanomaterials have caught the
attention of scientists, researchers, and manufacturers alike. The
global market for nanotechnology is expected to reach $1 trillion by
2015. Ongoing research activities harness its potential for the overall
betterment of the society.
“Nanobiotechnology is an emerging area that provides unlimited
opportunities in product development. This new technology speeds up
diagnostic processes; develops accurate engineered nanotools for the
prevention, diagnosis and treatment of diseases; facilitates early
detection of cancer, heart and other rare diseases; enhances drug
discovery; enables targeted drug delivery; opens doors for nanomedicine
by imparting stem cell applications; paves way for effective diagnosis
and treatment of cardiovascular disease; and strengthens tissue
engineering by providing bioactive nanomaterials for smart
implantation,� says Mr Puneet Mehrotra, director, Nano Science and
Technology Consortium (NSTC).
With over 250 corporate and institutional members, NSTC is
one-of-its-kind organization in India. The NSTC focuses on technology
transfer; facilitating global and local business opportunities,
training, education, publications and collaborative processes in
nanotechnology.
The Industry
Indian companies like Lifecare Innovations, Dabur Research Foundation
and Imgenex India; and research institutes such as Nichi-In Center for
Regenerative Medicine (NCRM) are focused on developing nanomedicine.
Nanomedicine makes use of nanoparticles for developing newer drug
delivery systems against cancer, diabetes, fungal infections and viral
infections.
Since its inception in 2000, Haryana-based Lifecare Innovations has
been working on nano drugs. The company has a number of products at
different stages of development. Their first product, Fungisome, a
nanosomal amphotericin B, is India's first nano drug. The drug offered
the opportunity to make a precision targeted delivery of encapsulated
amphotericin B to life-threatening fungal infections. “In 2003, we
started work on application of its proprietary oral sustained release
nanotechnology – the first application being anti-TB drugs
combinations. The preclinical studies were completed four-years ago,
but the Drug Controller General of India (DCGI) took three years to
understand and grant the company to conduct phase I clinical trial.
Promising results of the nano drugs for TB delineated that the long
duration sustained release would help reduce dosing frequency from
daily to two-three times a month, which would have understandable
advantages of logistics, socio-economical and treatment economics. It
is a celebrated technology in R&D circles but industry response is
lukewarm as TB patients are predominantly served by
government-controlled programs and industry is reluctant to invest is
neglected diseases,� says Dr Jitendra N Verma, managing director,
Lifecare Innovations.
Applications of
Nanobiotechnology
Nanopharmaceutical
Drug Discovery
- Gold nanoparticles and quantum dots are used for tracking
molecular properties in livening cells.
- Nanolaser helps to halt the progression of
neurodegenerative diseases.
- Nanoparticles enable cell targeting with attached small molecules.
Drug Delivery
- Protects drug against premature degradation
- Enables sustained release of a drug to maintain a long-lasting
drug concentration
- Diminishes adverse side-effects
- Enhances efficacy of a drug by delivering the drug to the
diseased tissue.
Drug Production
- Tablet design
- Tablet production system
- Tablet compression
Nanomedicine
- Nanodiagnostic devices
- Nanosurgery tools
- Nanooncology
- Nanoneurology
- Nanocardiology
- Nanoorthopedics
- Nanoophthalmology
- In treatment of infections
Tissue
engineering
- In natural musculoskeletal tissues
- Nanofibrous scaffolds are used in bones,
cartilages, muscles and ligaments
“The experience of sustained Release Nano-TB, however, encouraged more
applications. We are working as part of five-organization consortium
including ICGEB, New Delhi; BITS, Pilani; and University of Toronto
under ISTP Canada-DBT India collaborative program where we are
responsible for developing single dose sustained release oral drug for
malaria treatment. We have nano-antiinfectives, anti-cancer and
anti-inflammatory drugs, and pain killers in pipeline. In the next
three-to-five years, we aim to bring these novel drugs to the
patients,� adds Dr Verma.
Dabur Research Foundation (DRF), a contract research organization based
in Uttar Pradesh, has developed and standardized electron and
fluorescence microscopy-based methods, coupled with bioanalytical
techniques like HPLC and LC/MS to quantitate intracellular uptake and
localization of targeted nanoparticle devices. This technique enables
it to evaluate the intracellular accumulation of drugs and its
sub-cellular distribution and localization. This in-turn helps to form
a correlation with the biological activity of nano-delivery systems.
DRF currently offers these models as a service to pharma
and biotech industry.
“DRF developed and launched nanotech-based chemotherapy in India. This
nanoscale drug delivery system for the widely used anti-cancer agent,
paclitaxel, was the first-of-its-kind in India. The paclitaxel nano
drug is a cremophor-free water soluble formulation and is indicated as
a safe therapy for advanced breast, non-small cell lung and ovarian
cancers,� says Dr Manu Jaggi, director (R&D), Dabur Research
Foundation.
DRF's nanoparticle drug delivery devices such as Nanoxel enable the
therapy to take a preferential course to cancerous cells and directly
interact with tumor causing agents. This opens a larger window for
anti-tumor activity. It also ensures that the patient receives full
measure of the therapy while limiting the adverse side-effects and
toxicity affected by the drug,” adds Dr Jaggi.
Orissa-based biotech company Imgenex India is a leading developer of
monoclonal antibodies in India. The company has been using nano
particles in developing biosimilars, and has a strong program in the
development of biosimilar therapeutic monoclonal antibodies (mAbs).
“Imgenex India plans to improve the efficacy of the biosimilar
antibodies by encapsulating them in nanoparticles and make them as
biobetters or biosuperiors, which may be defined as antibodies that are
aimed at similar targets and carry similar indications as existing
products, but are with improved stability and dosage,” says Mr Sujay
Singh, CEO and president, Imgenex India.
“The protein and peptide drugs can exploit the development of
innovative systems which provide for controlled, prolonged or targeted
delivery, improved stability during storage and delivery, reduced
adverse effects, increased bioavailability, improved patient compliance
and allow for administration through the desired route while coping
with cost-containment therapeutic protocols. These can be achieved
using nanotechnology. Delivery of osteoclast inhibitory peptides using
nanotechnology-based platform for the treatment of osteoporosis is one
of the major projects at Imgenex India,” adds Mr Singh.
Imgenex India is also working on formulation of special media
supplement to induce pluripotent stem cells (iPS cells) from adult
somatic cells. The company plans to add nanoparticle-loaded recombinant
transcription factor proteins that are required for iPS cell generation
to the cell culture media. These nanoparticles will allow controlled
release of transcription factors into the culture media for induction
and maintenance of iPS cells from adult somatic cells. This project is
being carried out by a SBIRI funding from the Department of Biology,
India, in collaboration with Dr Sanjeeb Sahoo from Institute of Life
Sciences, Orissa. This technology will provide the ability to create
patient specific iPS cells for understanding disease progression and
screen for therapeutic strategies.
![](../Biospecial-Manu-Jaggi.jpg)
"
DRF's
Nanoparticle drug delivery devices such as Nanoxel enable the therapy
to take a preferential course to cancerous cells and directly interact
with tumor causing agents"
— Dr Manu Jaggi
director (R&D), Dabur Research Foundation
Chennai-based Nichi-In Center for Regenerative Medicine (NCRM) too has
been working on developing a nanomaterial-based artificial cornea. NCRM
is an Indo-Japan joint venture carrying out research, training and
clinical applications-protocol development in regenerative medicine,
with emphasis on stem cells, progenitor cells and autologous adult
cells with regenerative capability. NCRM is also developing a
nanomaterial and processing methodology for lab-based expansion of
hematopoietic stem cells, which would help blood cancer patients.
Commenting on NCRM's initiatives on nanobiotech, Dr Samuel JK Abraham,
director, NCRM says, “NCRM has been working with approximately 270
different nanomaterials and technologies in specialties such as
ophthalmology (corneal stem cell regeneration), orthopedics (cartilage
injury repair), and hematology (expansion of hematopoietic stem cells).
Recently NCRM along with our global headquarters – Nichi-In
International, Japan – and Kawamura Institute of Chemical Research,
Japan, have filed a joint patent application on a nano-sheet which
promotes the in vitro expansion of corneal endothelial precursors and
their application in vivo, in treating corneal blindness.”
In the anti-aging research we are working on developing nano-polymer
scaffolds to sustain the cells in zero-gravity and micro-gravity so
that the damages to cells during lab expansion or storage for longer
periods could be minimized so as to preserve their youthfulness,” adds
Dr Abraham.
Opportunities
India has a huge potential to market nanotech products. However,
careful and selective investments in nanotechnology can certainly
catalyze the country's economic development and in near future, could
pave way for its transformation into a developed nation. Nanomedicine
has bright growth prospects in India with its related research being
carried out in various academic and scientific institution. Research
includes designing of drugs with greater degree of cell specificity,
improved therapeutic efficacy of delivered drug as well as to minimize
its cytotoxicity-related adverse effects.
"Delivery of osteoclast inhibitory peptides using
nanotechnology-based platform for the treatment of osteoporosis is the
one of the major projects at Imgenex India"
— Mr Sujay Singh
CEO and president, Imgenex India
Similarly, diagnostics is another area of research that is investigated
extensively with nanoparticle for early detection of the disease
thereby providing better prognosis. The undergoing research in the
field of nanomedicine mainly explores its application to provide
targeted drug therapy, diagnostics, tissue regeneration, cell culture,
biosensors and other tools in the field of molecular biology.
Besides public sector R&D institutions, various companies in India
are researching on nanomedicine, especially in the development of newer
drug delivery systems against cancer, diabetes, fungal infections,
viral infections and for gene therapy. “The pharmaceutical,
biotechnology and biomedical companies in India are concentrating on
nano-based platforms like fullerenes, nanotubes, quantum dots,
nanopores, dendrimers, liposomes, magnetic nanoprobes and
radio-controlled nanoparticles for developing smarter therapeutic
and diagnostic modalities,” observes Mr Singh of Imgenex India.
India has made significant inroads into the field of nanomedicine in
the last decade. This includes areas such as nano-diagnostics (in-vitro
and in-vivo sensing and imaging systems capable of quantifying and
visualizing the levels of various bio-molecules at the cellular level),
targeted drug delivery; and cell and tissue repair (synthetic growth of
tissue by targeted delivery). “Other areas include development of
nano-bioceramics that can repair bone and tissue; and aerosol sprays
that use nanoparticles to deliver drugs for the treatment of lung
cancer. This ability to manipulate biological systems at the molecular
level and the scientific initiatives taken thus far will certainly
contribute to medical advances in the years to come,” says Dr Jaggi of
DRF.
Challenges
Even though India has several opportunities in the area of
nanomedicine, the country faces some challenges in the form of funding,
IP and understanding the technology when it comes to global market.
“From my personal opinion, India is still in infancy with the
nanomaterial development. When compared to the developed nations, we
did not start basic research in nanomaterials well in advance and due
to lack of such original technologies in materials, processes and
methodologies we need to depend on already patented materials and
methodologies to accomplish end-product developments,” says Dr Abraham
of NCRM.
“Indian researchers and industry both are glued to the generics and
biosimiliars bandwagon that does not allow them to think anew and come
up with a blockbuster. Regulatory regime also does not improve the
situation. On one hand, new things that deserve approvals are hard to
understand and so gets delayed, while on the other hand novel drug
delivery system in the name of generics get clearance without requisite
clinical trials. Same is the situation with clinicians. Any new drug
introduced by an MNC despite having well-known and documented narrow
activity becomes a drug of choice. For India to take advantage of its
full potential of novel technologies, this mindset needs to change, ”
says Dr Verma of Lifecare Innovations.
According to Dr Verma one important change required is in the area of
IP protection. Drugs, biotherapeutics, vaccines and other healthcare
products take around 10-15 years from concept to commercialization
because of requisite trials and resultant multi-stage regulatory
clearance process, whereas non-medical innovations can hit the market
immediately. This long duration consumes major part of the patent life
that serves as huge disincentive to develop new drugs. If newer
solutions are expected, patent life must be granted for a
post-marketing period.
Much of the work done until now has been focused on applications of
nanomedicine in drug discovery and drug delivery. Sharing his thoughts
on the advantages of nanomedicine, Dr Jaggi of DRF says “the
miniaturization of analytical, diagnostic procedures is another
important area which results in performing analytical procedures in the
lab on a much smaller scale. In the long-term, nanomedicine is expected
to provide the ability to undertake in vivo diagnostics coupled with
targeted and focused therapy.”
Looking at the opportunities and potential applications of
nanobiotechnology, the Government of India has been encouraging the
growth of the sector by funding nanobiotech projects under various
programs of DBT, DST, DSIR and ICMR. The Karnataka government too is
promoting nanobiotechnology and has allocated 14 acres of land to set
up the Indian Institute of Nano Science and Technology (IINST) in
Bangalore to strengthen nanobiotech R&D. Such government
initiatives will help India to move ahead in the nanobiotech race.